Turning Point Benefit Group’s Arvinas ARVN Stock Holding History

Turning Point Benefit Group’s Portfolio ARVN Stock Details ARVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7	Closed	-$64	–	856
2025 Q3	$64	Buy	+7	New	+$53	﹤0.01%	738

Other funds holding ARVN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Turning Point Benefit Group's ARVN Position: Q4 2025 in Review

Turning Point Benefit Group sold out of Arvinas (ARVN) in Q4 2025, closing a stake of 7 shares — an estimated $64 sold.

Turning Point Benefit Group first reported a position in ARVN in Q3 2025 and held it in 1 quarter. The position peaked at $64 in Q3 2025. 206 funds tracked by Wall St. Rank hold ARVN as of Q4 2025.

Turning Point Benefit Group reported no remaining Arvinas position as of Q4 2025 after selling out during the quarter.
Turning Point Benefit Group sold 7 Arvinas shares in Q4 2025, an estimated $64.
Turning Point Benefit Group first reported a position in Arvinas in Q3 2025 and held it in 1 quarter.
Turning Point Benefit Group's Arvinas position peaked at $64 in Q3 2025.
206 funds tracked by Wall St. Rank held Arvinas as of Q4 2025.

Based on Turning Point Benefit Group's 13F filing for Q4 2025, filed 30 Jan 2026.